---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014403"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:38:05.913304+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Q2 net loss $3.3M; cash $27.7M; ATRN-119 data Q4 2023

## Summary
- Net loss $3.3M ($0.87/sh) vs $98.3M loss in Q2 2022, driven by absence of $76M IPR&D charge from Atrin deal.
- Cash and equivalents $27.7M; management expects runway into Q4 2024.
- R&D expenses down to $2.2M from $6.8M; G&A down to $1.7M from $15.6M YoY.
- ATRN-119 Phase 1/2a enrollment ongoing; initial safety and PK data expected Q4 2023.
- Gabriela Gruia, M.D., appointed to Board of Directors; over 25 years clinical and regulatory experience.

## SEC filing metadata
- accession: 0001558370-23-014403
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/0001558370-23-014403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/apre-20230810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014403
- JSON: https://secwatch.observer/filing/0001558370-23-014403.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014403.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $3.3 million, EPS $0.87 per basic share.
  - Period: the quarter ended June 30, 2023
  - Net income: $3.3 million
  - EPS: $0.87 per basic share
  - Result: reported results
  source text: The Company reported a net loss of $3.3 million ($0.87 per basic share) on approximately 3.7 million weighted-average common shares outstanding for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/0001558370-23-014403-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.